Methods and compositions for immunomodulation
AssigneeNodality, Inc.
InventorsAndrew Hotson, Rachael Hawtin, Andrew T. Conroy, Erwan Le Scolan
Life of this patent
Estimating the term…
Abstract
The invention relates to immunomodulation of cells and the detection and use thereof, for example, in drug screening, including methods, compositions and systems therefor, or in an aspect of healthcare, such as prognosis, diagnosis, an aspect of treatment, monitoring, and the like, and methods, compositions, and systems therefor.
Claims43
A method of treating a patient suffering from cancer comprising treating the patient with a treatment;
- wherein an aspect of treating the patient with the treatment is based on an outcome of a treatment decision process, wherein the treatment decision process comprises consideration of at least two of a first, second, and/or third quantitative value, or a value or values derived from the at least two quantitative values;
- and
- wherein the first, second, and third quantitative values are obtained from results of a first, second, and/or third assay, respectively, wherein
- (a) the first assay comprises determining surface expression levels of a first immunomodulatory receptor (IMR) of a first cell population cell population (CP) in a first sample from the patient;
- (b) the second assay comprises determining functional status of a second IMR in single cells of a second CP or a subpopulation thereof in a second sample from the patient;
- and
- (c) the third assay comprises determining surface expression levels of an IMR ligand (IMRL) for a third IMR in a third cell population in a third sample from the patient.
(canceled)
4-7. (canceled)
-11. (canceled)
-23. (canceled)
(canceled)
(canceled)
-35. (canceled)
(canceled)
-41. (canceled)
A kit comprising
- (i) a distinguishably detectable binding element configured for use in binding to and distinguishably detecting a first intracellular element, wherein a change in the expression level and/or activation level of the first intracellular element in a cell of an immune cell type in response to exposure of the cell to an activator of the immune cell type is indicative of activation of the cell;
- and
- (ii) a distinguishably detectable binding element configured for use in binding to and distinguishably detecting a cell surface IMR on the cell or a cell surface IMRL on a cell of a population of cells of a non-immune cell type, and, optionally,
- (iii) the activator.
(canceled)
(canceled)
(canceled)
-69. (canceled)
A method for screening a first agent at a first screening level comprising
- (i) contacting a first immune cell population expressing a first IMR on their surfaces with the first agent and activating cells of the first population by contacting them with an activator;
- (ii) activating cells of a second immune cell population expressing the first IMR on their surfaces that have not been contacted with the first agent by contacting them with the activator;
- (iii) determining
- (a) expression levels of an intracellular expression element in single cells of the first population or a subpopulation thereof and expression levels of the intracellular element in single cells of the second population or a subpopulation thereof, wherein the intracellular expression element is an element whose expression levels changes upon activation of the cells of the first and second immune cell populations, and/or
- (b) activation levels of an intracellular activatable element in single cells of the first population or a subpopulation thereof and activation levels of the intracellular activatable element in single cells of the second population or a subpopulation thereof, wherein the intracellular activatable element is an activatable element whose activation level changes upon activation of the a cell of the first and second immune cell populations;
- and
- (iv) making a determination to send or not send the agent to a second screening level based on the results of (iii).
-107. (canceled)
A method of treating a patient suffering from a pathological condition comprising
- treating the patient with a treatment for the condition, wherein an aspect of treating the patient with the treatment is based on an outcome of a treatment decision process comprising consideration of a quantitative value, or a value or values derived from the quantitative value, wherein the quantitative value is obtained from results of an assay comprising determining functional status of an IMR in single cells of a immune cell population or a subpopulation thereof in a sample from the patient.
(canceled)
113-117. (canceled)
Dependencies are inferred from the claim text.